spacer
spacer

Search 

DrugBank target: Q8IUZ5

DrugBank target: Q8IUZ5 (AT2L2_HUMAN)     

5-phosphohydroxy-L-lysine phospho-lyase

Alanine--glyoxylate aminotransferase 2-like 2.

Function

Catalyzes the pyridoxal-phosphate-dependent breakdown of 5-phosphohydroxy-L-lysine, converting it to ammonia, inorganic phosphate and 2-aminoadipate semialdehyde. {ECO:0000269|PubMed:22241472}..

Enzyme

4.2.3.134   [EC->PDB]   [IntEnz]   [ExPASy]   [KEGG]  

Catalytic activity

(5R)-5-phosphonooxy-L-lysine + H(2)O = (S)-2- amino-6-oxohexanoate + NH(3) + phosphate.

Disease(s)

Phosphohydroxylysinuria (PHLU) [MIM:615011]: A condition characterized by elevated phosphohydroxylysine in the urine. There is no clinical phenotype associated with this finding other than the urinary metabolites. {ECO:0000269|PubMed:23242558}. Note=The disease is caused by mutations affecting the gene represented in this entry.

Structures

There are currently no structures for this UniProt code in the PDB.

Schematic diagram of Pfam domains in target sequence

Key:    PfamA domain

Sequence length: 450 a.a.

Approved nutraceuticals targeting this protein

The DrugBank database identifies 1 nutraceutical for this target protein:

 

Generic name: DB00160 l-alanine
ALA
Formula: C3H7No2
Structure: There are 1662 PDB structures containing this molecule although none are bound to the above target protein.

  spacer

spacer